Your browser doesn't support javascript.
loading
HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.
Robin, M; Porcher, R; Adès, L; Raffoux, E; Michallet, M; François, S; Cahn, J-Y; Delmer, A; Wattel, E; Vigouroux, S; Bay, J-O; Cornillon, J; Huynh, A; Nguyen, S; Rubio, M-T; Vincent, L; Maillard, N; Charbonnier, A; de Latour, R P; Reman, O; Dombret, H; Fenaux, P; Socié, G.
Afiliación
  • Robin M; 1] Hematologie - Transplantation; Assistance Publique Hôpitaux de paris (AP-HP), Hôpital Saint Louis, Paris, France [2] University Paris VII, Denis Diderot, Paris, France [3] Inserm U 1160, Paris, France.
  • Porcher R; 1] Team METHODS, Epidemiology and Statistics Sorbonne Paris Cité Research Centre UMR 1153, Inserm, Paris Descartes University, Paris, France [2] AP-HP, Hôpital Hôtel-Dieu, Centre d'Épidémiologie Clinique, Paris, France.
  • Adès L; Hématologie sénior, Assistance Publique Hôpitaux de paris (AP-HP), Hôpital Saint Louis and Hôpital Avicenne, Paris, France.
  • Raffoux E; Hématologie adulte, Assistance Publique Hôpitaux de paris (AP-HP), Hôpital Saint Louis, Paris, France.
  • Michallet M; Hématologie, CHU, Lyon, France.
  • François S; Hématologie, CHU, Angers, France.
  • Cahn JY; Hématologie, CHU,UMR 5525 CNRS-UJF, Grenoble, France.
  • Delmer A; Hématologie, CHU, Reims, France.
  • Wattel E; Hématologie, CHU, Lyon, France.
  • Vigouroux S; Hématologie, CHU, Bordeaux, France.
  • Bay JO; Hématologie, CHU, Clermont-Ferrand, France.
  • Cornillon J; Hématologie, Institut de Cancérologie de la Loire, Saint-Etienne, France.
  • Huynh A; Hématologie, CHU, Toulouse, France.
  • Nguyen S; Hématologie, hôpital de La Pitié Salpétrière Assistance Publique Hôpitaux de paris (AP-HP), Hôpital Saint Louis, Paris, France.
  • Rubio MT; Hématologie, hôpital Saint-Antoine, Assistance Publique Hôpitaux de paris (AP-HP), Hôpital Saint Louis, Paris, France.
  • Vincent L; Hématologie, CHU, Montpellier, France.
  • Maillard N; Hématologie, CHU, Poitiers, France.
  • Charbonnier A; Hématologie CHU, Amiens, France.
  • de Latour RP; 1] Hematologie - Transplantation; Assistance Publique Hôpitaux de paris (AP-HP), Hôpital Saint Louis, Paris, France [2] University Paris VII, Denis Diderot, Paris, France [3] Inserm U 1160, Paris, France.
  • Reman O; Hématologie CHU, Caen, France.
  • Dombret H; 1] University Paris VII, Denis Diderot, Paris, France [2] Hématologie sénior, Assistance Publique Hôpitaux de paris (AP-HP), Hôpital Saint Louis and Hôpital Avicenne, Paris, France.
  • Fenaux P; 1] University Paris VII, Denis Diderot, Paris, France [2] Hématologie sénior, Assistance Publique Hôpitaux de paris (AP-HP), Hôpital Saint Louis and Hôpital Avicenne, Paris, France.
  • Socié G; 1] Hematologie - Transplantation; Assistance Publique Hôpitaux de paris (AP-HP), Hôpital Saint Louis, Paris, France [2] University Paris VII, Denis Diderot, Paris, France [3] Inserm U 1160, Paris, France.
Leukemia ; 29(7): 1496-501, 2015 Jul.
Article en En | MEDLINE | ID: mdl-25676424
Allogeneic hematopoietic stem cell transplantation (HSCT) is considered the only a curative treatment in patients with higher risk myelodysplastic syndrome (MDS), although demethylating agents (DMA) have been reported to improve survival. The advantage of HSCT over other treatment comes from retrospective studies and the aim of the current study was to prospectively test this hypothesis, analyzing in particular patients from the pre-transplant period to avoid the selection bias of performing transplantation. This study was conducted to compare overall survival in MDS patients candidates to transplantation according to donor availability. The majority of patients (76%) received a treatment with DMA after registration, 69% had a human leukocyte antigen (HLA)-identical donor, 70% of whom were transplanted. Baseline patient and disease characteristics were similar according to donor availability. Four-year overall survival was significantly better in patients with an HLA matched donor (37%) compared to patients without donor (15%). There was also evidence that this overall survival advantage was because of transplantation. Mortality risk was decreased after transplantation but it became significant only after the second year post transplant, because of early transplant-related mortality. Our results appear to justify, in higher risk MDS, a transplantation approach in all potential candidates who have an HLA identical donor.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Protocolos de Quimioterapia Combinada Antineoplásica / Trasplante de Células Madre / Antígenos HLA Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Protocolos de Quimioterapia Combinada Antineoplásica / Trasplante de Células Madre / Antígenos HLA Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido